$AUTL

Autolus Therapeutics plc

CIK:0001730463|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Total revenue, net	$ 45,689	$ 20,923	$ 71,907	$ 29,905
Cost and operating expenses:
Cost of sales	(20,468)	(24,445)	(45,036)	(42,396)
Research and development expenses, net	(27,898)	(27,430)	(49,108)	(54,164)
Selling, general and administrative expenses	(41,161)	(30,265)	(81,114)	(59,802)
Loss from operations	(43,838)	(61,217)	(103,351)	(126,457)
Other income (expense):
Other income, net	181	135	281	262
Foreign exchange gains (losses), net	460	1,499	(2,207)	2,680
Interest income	1,877	5,234	4,346	11,371
Interest expense, net	2,674	6,829	(8,450)	(3,314)
Total other income (expenses), net	5,192	13,697	(6,030)	10,999
Net loss before income tax	(38,646)	(47,520)	(109,381)	(115,458)
Income tax expense	(465)	(397)	(1,328)	(2,623)
Net loss	(39,111)	(47,917)	(110,709)	(118,081)
Other comprehensive (loss) income:
Foreign currency exchange translation adjustment	538	18,990	(592)	29,658
Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of $0, $0, $0 and $0, respectively	(12)	(22)	(153)	378
Total other comprehensive income (loss), net of tax	526	18,968	(745)	30,036
Total comprehensive loss	$ (38,585)	$ (28,949)	$ (111,454)	$ (88,045)
Basic net loss per ordinary share (in usd per share)	$ (0.15)	$ (0.18)	$ (0.42)	$ (0.44)
Diluted net loss per ordinary share (in usd per share)	$ (0.15)	$ (0.18)	$ (0.42)	$ (0.44)
Weighted-average basic ordinary shares (in shares)	266,158,829	266,141,411	266,151,170	266,134,021
Weighted-average diluted ordinary shares (in shares)	266,158,829	266,141,411	266,151,170	266,134,021
Product revenue, net
Total revenue, net	$ 45,672	$ 20,923	$ 71,890	$ 29,905
License revenue
Total revenue, net	$ 17	$ 0	$ 17	$ 0

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (110,709)	$ (118,081)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation on property and equipment	4,370	4,075
Amortization of intangible assets	979	570
Inventory reserves and write-offs	3,100	3,244
Loss on disposal of property and equipment	2	3
Share-based compensation net of amounts capitalized	8,160	7,160
Interest expense accrued on liabilities related to future royalties and milestones, net	8,306	3,294
Accretion of available-for-sale securities	(1,227)	(5,103)
Foreign exchange differences	3,403	(5,702)
Non-cash operating lease expense	1,764	1,943
Impairment of operating lease right-of-use assets and related property and equipment	293	0
Deferred income tax	772	871
Changes in operating assets and liabilities:
Decrease in prepaid expenses and other current assets	20,489	5,452
Decrease (increase) in prepaid expenses and other non-current assets	82	(4,701)
Increase in inventories, net	(3,734)	(21,538)
Increase in accounts receivable, net	(20,375)	(26,726)
(Decrease) increase in accounts payable	(1,840)	3,395
Increase in deferred revenue	0	2,100
Decrease in accrued expenses and other liabilities	(5,552)	(5,237)
Increase in operating lease liability	1,331	6,635
Net cash used in operating activities	(90,386)	(148,346)
Cash flows from investing activities:
Acquisition of property and equipment	(3,601)	(15,520)
Purchases of marketable securities: available-for-sale debt securities	(14,721)	(119,299)
Proceeds from maturities and redemptions of marketable securities: available-for-sale debt securities	182,373	171,187
Net cash provided by investing activities	164,051	36,368
Cash flows from financing activities:
Proceeds from the exercise of share options	3	0
Payments of liabilities related to future royalties and milestones, net	(4,206)	(768)
Net cash used in financing activities	(4,203)	(768)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(2,188)	9,273
Net increase (decrease) in cash, cash equivalents and restricted cash	67,274	(103,473)
Cash, cash equivalents and restricted cash, beginning of period	105,636	228,805
Cash, cash equivalents and restricted cash, end of period	172,910	125,332
Unaudited supplemental cash flow information
Cash paid for income taxes	1,307	1,038
Unaudited supplemental non-cash flow information
Property and equipment purchases included in accounts payable or accrued expenses	158	2,114
Leased assets obtained in exchange for operating lease liabilities	11,654	0
Capitalized implementation costs included in accounts payable and accrued expenses	209	494
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets:
Cash and cash equivalents	171,414	123,825
Restricted cash	1,496	1,507
Total cash, cash equivalents and restricted cash	$ 172,910	$ 125,332

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 171,414	$ 104,132
Marketable securities - Available-for-sale debt securities	30,216	196,578
Restricted cash	1,496	1,503
Accounts receivable, net	44,392	24,024
Inventories, net	33,431	33,209
Prepaid expenses and other current assets	55,142	76,469
Total current assets	336,091	435,915
Non-current assets:
Property and equipment, net	60,523	63,563
Intangible assets, net	18,532	19,809
Prepaid expenses and other non-current assets	165	249
Operating lease right-of-use assets, net	74,111	64,940
Long-term deposits	1,016	1,032
Deferred tax asset	2,788	3,560
Total assets	493,226	589,068
Current liabilities:
Accounts payable	1,366	3,083
Accrued expenses and other liabilities	48,735	55,792
Operating lease liabilities, current	5,789	4,565
Liabilities related to future royalties and milestones, net - current	12,900	10,000
Total current liabilities	68,790	73,440
Non-current liabilities:
Operating lease liabilities, non-current	77,723	66,822
Liabilities related to future royalties and milestones, net - non-current	271,400	270,200
Other long-term payables	474	477
Total liabilities	418,387	410,939
Commitments and contingencies
Shareholders’ equity:
Additional paid-in capital	1,578,271	1,570,107
Accumulated other comprehensive loss	(6,101)	(5,356)
Accumulated deficit	(1,497,461)	(1,386,752)
Total shareholders’ equity	74,839	178,129
Total liabilities and shareholders’ equity	493,226	589,068
Ordinary Shares
Shareholders’ equity:
Ordinary and deferred shares, value	12	12
Deferred Shares
Shareholders’ equity:
Ordinary and deferred shares, value	0	0
Deferred Class B Shares
Shareholders’ equity:
Ordinary and deferred shares, value	118	118
Deferred Class C Shares
Shareholders’ equity:
Ordinary and deferred shares, value	$ 0	$ 0